Protai bio

Drug discovery startup based on Proteomics and AI

The AIMS™ (AI-Mass-Spectrometry) platform integrates mass-spectrometry-based structural proteomics, AI-based structural modeling and experimental validation in the company's own wet labs. Structural proteomics methods such as HDX-MS and XL-MS supply experimental data on dynamic protein conformations and interactions, which AI models use to model large protein complexes, reveal transient druggable pockets (for example in TNFα) and support rational design and lead optimization of small molecules and degraders. AIMS-Fold, a structural-proteomics-guided generative AI framework, feeds experimental structural proteomics measurements directly into pretrained structure-prediction models, steering generative sampling toward conformations consistent with biological and biophysical constraints rather than relying only on sequence and evolutionary signals. The company built a proteomics database of more than 50,000 clinical samples by harmonizing large clinical datasets, and gained access to more than 100,000 banked clinical samples through hospital collaborations. It has also reported using AlphaFold and NVIDIA NIM for protein complex structure prediction.

Physicians.

Eran Seger - CEO & Co-Founder

Kirill Pevzner - CTO & Co-Founder